

**A 2-Part Series:**

**Therapeutic Considerations of Carbapenem Antibiotics**

George P. Allen, Pharm.D.

**References**

1. Fish DN, Singletary TJ. Meropenem, a new carbapenem antibiotic. *Pharmacother* 1997;17(4):644-669.
2. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. *Scand J Infect Dis* 1995;Suppl 96:5-10.
3. Richerson MA, Ambrose PG, Quintiliani R, et al. Formulary review of the carbapenems: comparison of imipenem and meropenem. *Conn Med* 1998;62(3):165-169.
4. Dagan R, Velghe L, Rodda JL, et al. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. *J Antimicrob Chemother* 1994;34:175-179.
5. Basoli A, Meli EZ, Mazzocchi P, et al. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. *Scand J Infect Dis* 1997;29:503-508.
6. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. *J Antimicrob Chemother* 1995;35:139-148.
7. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem in the treatment of serious bacterial infections in hospitalized patients. *J Antimicrob Chemother* 1996;38:523-537.
8. Garau J, Blanquer J, Cobo L, et al. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. *Eur J Clin Microbiol Infect Dis* 1997;16(11):789-796.
9. Geroulanos SJ, Depuydt P, van Kershaver B, et al. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. *J Antimicrob Chemother* 1995;36(Suppl A):191-205.
10. Hamacher J, Vogel F, Lichey J, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients – a comparison of meropenem and imipenem/cilastatin. *J Antimicrob Chemother* 1995;36(Suppl A):121-133.
11. Maggioni P, Di Stefano F, Facchini V, et al. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin. *J Chemother* 1998;10(2):114-121.
12. Nichols RL, Smith JW, Geckler RW, et al. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. *South Med J* 1995;88(4):397-404.
13. Shah PM, Heller A, Fuhr H. Addendum: empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. *Infection* 1996;24(6):76/480-80/484.

A University of Washington / Harborview Medical Center Drug Information Center publication  
Distributed monthly by authority of the Pharmacy and Therapeutics Committee  
Editor: Nelda A. Murri, Pharm.D. (206) 548-6347 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.  
Department of Pharmacy Services / School of Pharmacy

Copyright © 1999 by the University of Washington  
Also published on the World Wide Web at <http://weber.u.washington.edu/~druginfo>  
No material may be reproduced in whole or in part without written permission from the editor.

14. Wong VK, Wright HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. *Pediatr Infect Dis J* 1991;10:122-125.
15. Asensi F, Pérez-Tamarit D, Otero MC, et al. Imipenem-cilastatin therapy in a child with meningitis caused by a multiply resistant pneumococcus [Letter]. *Pediatr Infect Dis J* 1989;8(12):895.
16. Asensi F, Otero MC, Pérez-Tamarit D, et al. Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus. *J Chemother* 1993;5(2):133-134.
17. Klugman KP, Dagan R, Williams KJ, et al. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. *Antimicrob Agents Chemother* 1995;39(5):1140-1146.
18. Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. *J Antimicrob Chemother* 1995;36(Suppl A):85-97.
19. Chmelik V, Gutvirth J. Meropenem treatment of post-traumatic meningitis due to *Pseudomonas aeruginosa*. [Letter] *J Antimicrob Chemother* 1993;32:922-923.
20. Donnelly JP, Horrevorts AM, Sauerwein RW, et al. High-dose meropenem in meningitis due to *Pseudomonas aeruginosa* [Letter]. *Lancet* 1992;339(May 2):1117.
21. Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. *J Antimicrob Chemother* 1995;36(Suppl A):207-223.
22. Saxon A, Adelman DC, Patel A, et al. Imipenem cross-reactivity with penicillin in humans. *J Allergy Clin Immunol* 1988;82(Aug):213-217.
23. Calandra GB, Brown KR, Grad LC, et al. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. *Am J Med* 1985;78(Suppl 6A):73-78.
24. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. *Am J Med* 1988;84(May):911-918.
25. Day IP, Goudie J, Nishiki K, et al. Correlation between *in vitro* and *in vivo* models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. *Toxicol Lett* 1995;76:239-243.
26. DeSarro A, Ammendola D, Zappala M, et al. Relationship between structure and convulsant properties of some b-lactam antibiotics following intracerebroventricular microinjection in rats. *Antimicrob Agents Chemother* 1995; 39:232-237.
27. Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice *J Antimicrob Chemother* 1989;24:307-309.
28. Brotherton TJ, Kelber RL. Seizure-like activity associated with imipenem. *Clin Pharm* 1984;3(Sep-Oct):536-540.
29. Eng RH, Munsif AN, Yangco BG, et al. Seizure propensity with imipenem. *Arch Intern Med* 1989;149(Aug):1881-1883.
30. Job ML, Dretler RH. Seizure activity with imipenem therapy: incidence and risk factors. *DICP Ann Pharmacother* 1990;24(may):467-469.
31. Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. *Pediatr Infect Dis J* 1996;15(8):749-757.
32. Stuart RL, Turnidge J, Grayson ML. Brief reports: safety of imipenem in neonates. *Pediatr Infect Dis J* 1995;14(9):804-805.

33. Semel JD, Allen N. Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. *South Med J* 1991;84(4):465-468.
34. Tse CS, Vera FH, Desai DV. Seizure-like activity associated with imipenem-cilastatin [Letter]. *DICP* 1987;21(July/Aug):659-60.
35. Guess HA, Resseguie LJ, Melton LJ, et al. Factors predictive of seizures among intensive care unit patients with gram-negative infections. *Epilepsia* 1990;31(5):567-573.
36. Guglielmo BJ, Jacobs RA. Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin [Letter]. *Am J Health-Syst Pharm* 1996;53(Sep 1):2097-2098.
37. Nalin DR, Jacobsen CA. Imipenem/cilastatin therapy for serious infections in neonates and infants. *Scand J Infect Dis* 1987;Suppl 52:46-55.
38. Winston DJ, Ho WG, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, an imipenem alone. *Ann Intern Med* 1991;115(11):849-859.
39. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. *Antimicrob Agents Chemother* 1996;40(5):1108-1115.
40. Sanders WE, Sanders CC. Inducible  $\beta$ -lactamases: clinical and epidemiologic implications for use of newer cephalosporins. *Rev Infect Dis* 1988;10(4):830-838.
41. Reese RE, Betts RF (eds.). *A Practical Approach to Infectious Diseases*. Boston: Little, Brown and Co.; 1996:1218-1240.
42. Bradley JS. Selecting therapy for serious infections in children: maximizing safety and efficacy. *Diagn Microbiol Infect Dis* 1998;31:405-410.
43. Klugman KP, Dagan R. Carbapenem treatment of meningitis. *Scand J Infect Dis* 1995;Suppl 96:45-48.
44. Norrby SR. Neurotoxicity of carbapenem antibacterials. *Drug Safety* 1996;15(2):87-90.
45. Arrieta A. Use of meropenem in the treatment of serious infections in children: review of the current literature. *Clin Infect Dis* 1997;24(Suppl 2):S207-S212.